ESSA Pharma
- Country
- 🇨🇦Canada
- Ownership
- -
- Employees
- 50
- Market Cap
- $230.7M
- Introduction
ESSA Pharma, Inc. is a clinical stage pharmaceutical company. It engages in the business of developing small molecule drugs for the treatment of prostate cancer. The company was founded by Marianne D. Sadar and Raymond J. Andersen on January 6, 2009 and is headquartered in Vancouver, Canada.
ESSA Pharma Discontinues Masofaniten Trials, Initiates Strategic Review
ESSA Pharma has halted the clinical development of masofaniten after an interim analysis showed it was unlikely to meet the primary endpoint in combination with enzalutamide.
FDA Accepts Bayer's Nubeqa sNDA for Metastatic Hormone-Sensitive Prostate Cancer
The FDA has accepted Bayer's sNDA for Nubeqa (darolutamide) in combination with androgen deprivation therapy (ADT) for mHSPC.
ESSA Pharma Halts Masofaniten Development After Phase II Futility Analysis
ESSA Pharma discontinues development of masofaniten after a Phase II trial showed no significant benefit over enzalutamide alone in mCRPC patients.
ESSA Pharma Discontinues Phase II Masofaniten Trial for Prostate Cancer
ESSA Pharma halted its Phase II trial of masofaniten plus enzalutamide for metastatic castration-resistant prostate cancer (mCRPC) due to interim analysis results.
ESSA Pharma Discontinues Phase 2 Trial of Masofaniten Plus Enzalutamide in mCRPC After Futility Analysis
ESSA Pharma halted a phase 2 trial of masofaniten plus enzalutamide for metastatic castration-resistant prostate cancer (mCRPC) due to low likelihood of meeting the primary endpoint.
ESSA Pharma Discontinues Phase II Trial of Masofaniten in Prostate Cancer
ESSA Pharma halted its Phase II trial of masofaniten plus enzalutamide for metastatic castration-resistant prostate cancer (mCRPC) due to interim analysis results.
ESSA Pharma Halts Phase 2 Trial of Masofaniten Plus Enzalutamide in mCRPC
ESSA Pharma terminated a Phase 2 trial of masofaniten plus enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) due to futility analysis.
ESSA Pharma Halts Phase 2 Masofaniten Trial in Metastatic Castration-Resistant Prostate Cancer
ESSA Pharma terminated its Phase 2 trial of masofaniten plus enzalutamide for mCRPC after interim analysis showed no clear efficacy benefit over enzalutamide alone.
ESSA Pharma's Masofaniten Shows Promise in Metastatic Castration-Resistant Prostate Cancer
Masofaniten, combined with enzalutamide, demonstrates durable PSA reductions in mCRPC patients, with 88% achieving PSA90 across all dose cohorts.